AGC Biologics' Newsletter: Beyond the Bioreactor

AGC Biologics' Newsletter: Beyond the Bioreactor

Featured News

CompleCure Partners with AGC Biologics’ Chiba Site to Develop Advanced Anti-Cancer Therapeutic Using Pioneering AMDC Technology

9/23/24 - The therapeutic being developed aims to revolutionize breast cancer treatment and is designed to achieve complete remission with minimal side effects, significantly improving patient outcomes. Read the full press release.

AGC and MEDINET Strategic Partnership to Accelerate CGT CDMO Business in Japan

9/16/24 - AGC Biologics and MEDINET are working on a new collaboration to combine resources and grow the cell therapy CDMO resources available in Japan. By sharing best practices, scientific knowledge and learning from each other, we can work together to help improve the quality of CGT services in the APAC region. Learn about the partnership here.

AGC Biologics Strengthens Portfolio with Latest FDA Commercial Approval at Company’s CPH Facility

8/27/24 - AGC Biologics' Copenhagen Site achieved a significant milestone with U.S. FDA approval for a biosimilar indicated for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. This success highlights the site’s advanced single-use bioreactor technology, which scales production efficiently as demand grows. . Read the full press release.

AGC Biologics and NEC Bio Therapeutics Announce Collaboration to Manufacture Personalized Cancer Vaccines

8/7/24 - AGC Biologics and NEC Bio Therapeutics partnered to produce NECVAX-NEO1, an orally delivered, bacteria-based DNA vaccine targeting patient-specific tumor neoantigens. The partnership will focus on clinical development and GMP-compliant manufacturing in Germany, with clinical trials set to begin in 2024 and 2025. Read the full press release.

Uniting for Scalable, Cost-effective Antibody Production

Resin is costly and offers bioburden challenges that can slow timelines for clinical production. A new solution from The W.L. Gore - Protein A membrane devices - enables scalable, fully single-use biomanufacturing with fast cycling, higher productivity, and cost-efficient antibody production.

When you pair that with our extensive network of single-use technology, you get a flexible, cost-effective solution for antibody production from discovery to GMP-level manufacturing.

WATCH: Explore the future of mAb purification today!

Cell and Gene Meeting on the Mesa - October 7 - 9

Visit our website for more information or to set up a meeting with our business development reps attending the show.

CPHI Europe - October 8 - 10

Visit our website for more information or to set up a meeting with our business development reps attending the show.

BioJapan - October 9 - 11

Visit our website for more information or to set up a meeting with our business development reps attending the show.

Each month, we spotlight key content in the dynamic world of biotech. Whether it's the latest insights on cell and gene therapy, breakthroughs in biologics production, or cutting-edge industry trends, you'll find valuable knowledge here. If you're hungry for more, be sure to explore our full content library for in-depth resources and exclusive updates!

Dive into this month's featured webinar, white paper and site tour!


Webinar: Accelerating Cell Line Development from DNA to MCB

This on-demand webinar discusses important factors to consider when building a CLD strategy. Learn about workflows, timelines, and state-of-the-art technologies used in standard and adapted CLD processes. We also feature the diverse molecule types and our collaborative services that help to shorten timelines.

Watch for free today!


White Paper: A 3-Stage Exploration of CGT Process Development to Find Commercial Success

Dive into the details that truly matter when building efficient GMP processes to push CGT products from the clinic to commercial approvals.

Download this white paper and learn to create safe, streamlined process design, PPQ and CPV for cell and gene therapies.


Technical Site Tour: Seattle, Washington

Our AGC Biologics global headquarters site in Seattle has multiple mammalian lines for clinical and commercial production and new microbial services. Watch our site capabilities overview today or explore its complete capabilities on our official site page.

Meet Our Featured Employee!

We have an incredible team of people at AGC Biologics who work hard every day to help improve patients' lives. Get to know this month's featured team members.

Meet Henrik Stender Sode, a Technical Training Specialist in Copenhagen.

Jason Soung

Global BD Director at Yaohai Bio-Pharma

2mo

See you in Milan @Hall 3-G135 https://lnkd.in/gfndzVze

Like
Reply

To view or add a comment, sign in

Insights from the community

Others also viewed

Explore topics